CLINICAL TRIALS PROFILE FOR VATALANIB
✉ Email this page to a colleague
Clinical Trials for Vatalanib
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00056446 ↗ | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer | Completed | Bayer | Phase 3 | The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan. |
NCT00056446 ↗ | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer | Completed | Novartis Pharmaceuticals | Phase 3 | The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan. |
NCT00056459 ↗ | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. | Completed | Bayer | Phase 3 | To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment |
NCT00056459 ↗ | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. | Completed | Novartis | Phase 3 | To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment |
NCT00072475 ↗ | Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes. |
NCT00072475 ↗ | Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes | Completed | Alliance for Clinical Trials in Oncology | Phase 2 | RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes. |
NCT00088231 ↗ | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | Completed | Novartis | Phase 1/Phase 2 | The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic Myeloid Metaplasia (AMM). Another goal is to see how effective this combination treatment is. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Vatalanib
Condition Name
Clinical Trial Locations for Vatalanib
Trials by Country
Clinical Trial Progress for Vatalanib
Clinical Trial Phase
Clinical Trial Sponsors for Vatalanib
Sponsor Name